Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas (NCT00070070), a non-randomized phase 1 study. The primary outcome is Number of Participants With Dose Limiting Toxicities.

2. Clinical Question

3. Trial Design

This was a phase I, nonrandomized, unmasked, sequential trial with an enrollment of 6. The registry lists the status as completed. The start date was 2003-10-28, and the primary completion date was 2006-01-03. The record title concerns vaccine therapy in patients with transitional cell carcinomas; the official title specifies NY-ESO-1 protein immunization after cystectomy or nephroureterectomy.

The registered interventions were NY-ESO-1 protein, TICE®-strain BCG, and sargramostim. Cohort descriptions organize participants by HLA-A2 status and previous BCG therapy: positive status with previous BCG therapy, positive status without previous BCG therapy, negative status with previous BCG therapy, and negative status without previous BCG therapy. One participant in Cohort 4 did not have HLA-A2 status tested, so the cohort label does not establish that participant's status.

The descriptions state that NY-ESO-1 protein, 75 mcg, was given by intradermal injection every week for 6 weeks. They also mention BCG and skin testing with purified protein derivative. The complete regimen details, including a complete account of sargramostim administration, are not reported in the registry record. The intervention descriptions for some cohorts are truncated.

Because allocation was nonrandomized and the cohorts reflect different baseline classifications, cohort comparisons cannot be interpreted as randomized treatment contrasts. The registry record does not report a separate untreated or standard-care control arm. The sequential model is recorded, but further details about how participants entered or progressed through the sequence are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: All participants who received at least one study treatment. One participant in Cohort 4 did not have HLA-A2 status tested.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All participants who received at least one dose of study therapy.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Dose Limiting Toxicities, measured over up to 12 weeks.

The primary endpoint is the number of participants with dose-limiting toxicities, measured in participants and assessed for up to 12 weeks. The endpoint population includes participants who received at least one study treatment. A dose-limiting toxicity required an adverse event to be definitely, probably, or possibly related to study treatment and to meet one of the specified criteria: autoimmune phenomena of Grade 2 or higher; asymptomatic bronchospasm or generalized urticaria; or hematological or non-hematological toxicity of Grade 3 or higher. Participants who experienced a dose-limiting toxicity were removed from the study.

The registry states that adverse events were graded using National Cancer Institute Common Toxicity Criteria, Version 3.0. A count endpoint is useful in an early-phase safety assessment because it describes how many participants meet a prespecified toxicity definition during the stated observation period. It does not describe the timing, duration, or full severity distribution of events, and a count alone does not establish that an event was caused by treatment.

The registry record defines the endpoint but does not report the number of participants who met its dose-limiting toxicity definition. The adverse-event counts listed separately do not, on their own, identify which events satisfied the endpoint's attribution and grading criteria.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a participant count measure?

The primary endpoint is a count of participants meeting a defined dose-limiting toxicity criterion, rather than a continuous measurement or a time-to-event outcome. For a binary participant-level endpoint, each participant is classified according to whether the event definition was met during the observation period. The count communicates the number who met the definition; interpretation also depends on the number assessed and the way the outcome was defined.

General statistical explanation: a count is easy to understand, but it does not by itself convey the uncertainty around the underlying event frequency. With few participants, each outcome can have a substantial influence on the displayed proportion. Confidence intervals can express uncertainty around an estimated event frequency, but the registry record does not report a primary endpoint estimate or confidence interval.

Why does endpoint definition matter?

The record defines dose-limiting toxicity using toxicity grade, event type, and relationship to study treatment. This means that the endpoint is narrower than “any adverse event.” An event must meet the specified clinical criteria and be judged definitely, probably, or possibly related to study treatment to qualify. The registry also states that participants experiencing a dose-limiting toxicity were removed from study. These details are important when interpreting safety counts: counts of other adverse events cannot be substituted for the primary endpoint count without participant-level information showing that the endpoint criteria were met.

The reported assessment window is up to 12 weeks. Outcomes observed over a defined window depend on how long participants were followed and whether assessments were complete. The record does not report participant-level follow-up, the timing of individual adverse events, or details of any incomplete assessment.

What can cohort summaries establish?

The trial is nonrandomized and sequential. Participants were grouped according to HLA-A2 status and previous BCG therapy; the record does not describe a randomized allocation between treatment and control. General statistical explanation: random allocation helps make treatment groups comparable on average, while nonrandomized groups may differ in characteristics that also relate to outcomes. A raw difference between such groups cannot by itself isolate a treatment effect.

The cohort summaries are therefore descriptive. Their small counts do not support precise comparative conclusions, and the registry reports no formal analysis results. Cohort membership also should not be treated as a complete account of HLA-A2 status in Cohort 4 because one participant was not tested. No adjustment strategy or model for comparing cohorts is reported in the registry record.

How should planning calculations be read?

General statistical explanation: sample-size calculations describe how many participants or events might be needed under chosen assumptions to detect a specified effect with a chosen error rate and power. Such calculations are planning illustrations, not results observed in the trial and not a measure of the study's actual power after completion. The planning assumptions stated for the illustrations include a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The effect to detect is described as a stated fraction of an observed effect. These assumptions do not change the registry's description of this study as nonrandomized, and the record does not report that they were the trial's original design justification.

General statistical explanation: when data are sparse, approximations that rely on large samples may be less dependable. For a binary outcome, the number of participants with and without the event matters to uncertainty estimation. Over-dispersion is a concern in count-data models when variation exceeds what a model assumes; no count-data model or over-dispersion analysis is reported for this trial, and the primary endpoint is described as a participant count.

What statistical analyses are reported?

The registry record lists 4 outcome measures and 0 analyses. It specifies the primary outcome definition and lists secondary outcomes concerning NY-ESO-1 antibodies, CD4+ and CD8+ T-cell responses, and delayed-type hypersensitivity measured by induration and/or redness. However, results for these outcomes and inferential analyses are not reported in the registry record. There are no reported effect estimates, confidence intervals, or p-values for the primary endpoint in the record described.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Cohort 1", "Cohort 4")
n      <- c(1, 5)
events <- c(0, 0)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Cohort 1  1  0  0.0  0.0  97.5  0.0  79.3  1.3  84.2
ARM  Cohort 4  5  0  0.0  0.0  52.2  0.0  43.4  0.4  45.9

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 4 outcome measures: the primary count of participants with dose-limiting toxicities and secondary outcomes concerning NY-ESO-1 antibodies, CD4+ and CD8+ T-cell responses, and delayed-type hypersensitivity measured by induration and/or redness at each timepoint. The record does not report a multiplicity plan, including whether any outcome was designated for confirmatory testing or how repeated testing across outcomes or timepoints would be handled.

General statistical explanation: when many hypotheses are tested, the chance of at least one apparently positive finding can increase unless the analysis accounts for multiplicity. This concern is relevant when interpreting a collection of outcomes, but no inferential results are reported to evaluate, and no correction procedure is reported in the registry record.

Missing-data handling is not reported in the registry record. The record does not describe the amount or reasons for missing outcome assessments, imputation, sensitivity analyses, or how incomplete follow-up was handled. One participant in Cohort 4 did not have HLA-A2 status tested; this is a specific missing classification, not a report of missing primary-outcome data.

The primary endpoint population is described as all participants who received at least one study treatment. The record does not report a separate analysis population, an intention-to-treat analysis, or participant-level information showing how many received treatment or contributed endpoint data. The adverse-event summary lists cohort-specific counts at risk, but it does not report a formal analysis population for the primary endpoint. These omissions limit assessment of how completely the enrolled participants were represented in the outcome results.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The serious adverse-event summary lists 0 affected participants among 1 at risk in Cohort 1 and 0 among 5 at risk in Cohort 4. Cohort 2 and Cohort 3 each list 0 participants at risk in this summary. The deaths column lists 0 for every cohort. No top serious-event terms are listed.

For other adverse events, the summary lists 1 affected participant among 1 at risk in Cohort 1 and 5 affected among 5 at risk in Cohort 4. Cohort 2 and Cohort 3 again list 0 at risk. These are registry counts, not a comparison between randomized groups. The small cohort counts mean that the figures offer limited precision and cannot characterize the range of possible event frequencies.

“Other” events are not interchangeable with dose-limiting toxicities. The primary endpoint requires specific grading or event criteria and a stated relationship to treatment; the adverse-event summary does not establish which events met that definition. The registry record does not report a primary dose-limiting toxicity count, and the adverse-event counts should not be used to infer it.

13. What the Result Does, and Does Not, Mean

The record describes a phase I investigation of NY-ESO-1 protein immunization with registered BCG and sargramostim interventions in patients with transitional cell carcinomas after surgery. Its primary safety question is whether participants developed a dose-limiting toxicity during follow-up of up to 12 weeks. The endpoint definition is stated, but the number meeting that definition is not reported in the registry record.

The listed adverse-event summary shows no serious events or deaths in the cohort rows with participants at risk, alongside other adverse events in Cohort 1 and Cohort 4. These descriptive counts do not identify whether any event was dose-limiting, and the small enrollment limits the precision of safety estimates. Zero reported serious events in these groups does not demonstrate that serious events cannot occur.

The study does not provide a randomized treatment comparison. Differences between cohort summaries cannot establish whether an intervention caused an outcome or whether HLA-A2 status or previous BCG therapy modified an outcome. The record also does not report outcome estimates or analyses for the listed immune-response and delayed-type hypersensitivity outcomes.

Accordingly, the registry entry documents the study design, endpoint definitions, and selected safety counts, but it does not provide enough reported outcome information to estimate the primary endpoint or draw a comparative treatment conclusion. This is a description of what the record reports, not medical advice or a judgment about treatment.

14. Why This Trial Matters Statistically

This trial illustrates why a clearly defined endpoint and a reported endpoint result are both necessary for statistical interpretation. The record gives a detailed definition of dose-limiting toxicity, including event grades, qualifying conditions, treatment attribution, and the observation period. Yet the primary outcome count is not reported. Without that count, the central safety question cannot be answered from the registry entry, even though the endpoint itself is described.

The study also demonstrates the distinction between descriptive cohort summaries and randomized comparisons. Its nonrandomized structure and cohort groupings by HLA-A2 status and previous BCG therapy do not support causal interpretation of differences between groups. This matters particularly with an enrollment of 6, where cohort-level counts are small and a single participant's outcome can materially affect a summary.

Finally, the record separates several kinds of outcome information: dose-limiting toxicities, other adverse events, antibodies, T-cell responses, and delayed-type hypersensitivity. These are not interchangeable measures. A general safety count cannot replace a prespecified endpoint, and an immune-response measure does not itself establish a clinical effect. Statistical interpretation depends on matching the claim to the outcome definition, analysis, and population actually reported.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not report the primary endpoint result, despite defining dose-limiting toxicity and its assessment window. It also does not report effect estimates, confidence intervals, p-values, or analyses for the primary or secondary outcomes. The available adverse-event summaries therefore cannot establish how many participants met the primary endpoint definition.

Enrollment was 6, and the cohort rows are small. Such counts provide limited precision and cannot reliably characterize uncommon events. The study was nonrandomized and unmasked, and the cohorts differed according to HLA-A2 status and previous BCG therapy. These features limit causal comparison and leave potential group differences unresolved.

One participant in Cohort 4 did not have HLA-A2 status tested. The record does not report how missing outcome data or incomplete follow-up were handled, or whether all participants completed the stated assessment window. Complete administration details for the registered interventions are not reported; some cohort descriptions are truncated, and the sargramostim schedule is not reported in the registry record.

The record lists secondary immune-response outcomes but does not report their results or a plan for multiplicity. It also does not report a statistical analysis plan, sample-size justification, or details of interim analyses. The planning assumptions described for sample-size illustrations should not be read as the original trial design or as evidence of observed power.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas — NCT00070070.
• Registry record last updated 2022-10-12; status last verified 2022-10.
• Results first posted 2021-07-08.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT00070070 is a completed phase I, nonrandomized, unmasked, sequential trial with an enrollment of 6. It studied NY-ESO-1 protein immunization with registered TICE®-strain BCG and sargramostim interventions in patients with transitional cell carcinomas after surgery. The primary endpoint was the number of participants with dose-limiting toxicities over up to 12 weeks among participants who received at least one study treatment.

The record defines dose-limiting toxicity but does not report its primary outcome count or formal analyses. Adverse-event summaries list no serious events or deaths in cohort rows with participants at risk, and list other adverse events in Cohort 1 and Cohort 4. Those counts do not establish the primary endpoint result. Secondary immune-response outcomes are listed, but their results are not reported in the registry record.